A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Exclusion Criteria

• •MAIN PART:
• •1. Participants who received any other SARS-CoV-2 vaccine (except for the specified mRNA vaccine) or other experimental novel coronavirus vaccine prior to the trial.
• •2. Participant who received a booster vaccination (i.e. 3rd dose)
• •3. Participants who have close contact of anyone known to have COVID-19 within 14 days prior to the trial vaccination.
• •4. Participants who were tested positive for SARS-CoV-2 prior to the trial.
• •5. Participants who have traveled outside of Japan in the 30 days prior to the trial participation.
• •6. Participants with a clinically significant active infection or oral temperature \>= 38 degree Celsius within 3 days of the intended date of the first single booster vaccination.
• •7. Participants with body mass index (BMI) greater than or equal to 30 kg/m\^2 (BMI= weight in kg/ height in meters\^2)
• •EXTENSION PART:
• •8. Participants with a clinically significant active infection or oral temperature \>=38 degree Celsius within 3 days of the intended date of the second single booster vaccination.